Covista reported a strong first quarter, exceeding Wall Street’s forecasts for both revenue and non-GAAP earnings. Management noted that substantial enrollment growth across all segments, especially at Chamberlain and Walden universities, was the key factor in their performance. CEO Stephen Beard highlighted a return to positive total enrollment at Chamberlain, stating, ‘The operational changes we implemented are indeed effective.’ Improvements in marketing and application processes also played a significant role in these results, showcasing the company’s strategic execution. Now may be the right moment to consider investing in CVSA—explore our in-depth research report, available for free. Highlights from Covista (CVSA) Q1 CY2026 include: Revenue of $487 million, exceeding analyst predictions of $474 million (4.5% year-over-year growth, 2.7% beat); Adjusted EPS of $1.98, surpassing analyst estimates of $1.72 (14.9% beat); Adjusted EBITDA of $127.9 million versus analyst anticipations of $117.7 million (with a 26.3% margin, 8.6% beat); Annual revenue guidance raised slightly to a midpoint of $1.94 billion; Full-year Adjusted EPS guidance now set at $8.05, a 1.9% increase; Operating Margin consistent at 18.8% compared to the same quarter last year; Current Market Capitalization stands at $4.38 billion. While we appreciate management’s insights, analyst questions are often the most revealing part of earnings calls, addressing potential areas of concern or complex topics. Here are our Top 5 Analyst Questions from Covista’s Q1 Earnings Call: Ryan Griffin from BMO Capital Markets inquired about updates on employer partnerships like SSM. CEO Stephen Beard confirmed that SSM remains strong with ongoing discussions for new partnerships, although specifics weren’t shared. Griffin also questioned any potential shifts in fourth-quarter investments from Q3, to which CFO Robert Phelan clarified that additional investments were planned specifically for Q4, rather than being reallocated from the previous quarter. Jasper Bibb of Truist Securities asked about the reasons behind Chamberlain’s enrollment recovery and RN to BSN demand, with Beard attributing the positive turnaround to marketing enhancements and revived interest in post-licensure programs. Bibb further sought reassurance on application conversion rates at Chamberlain, and Beard assured that these rates have returned to historical norms following improvements in staff and processes. Jack Slevin from Jefferies asked about capital expenditure trends as new campuses are introduced, and Phelan noted that CapEx would increase in Q4, providing a benchmark for future rates as expansion progresses. Looking ahead, we will closely monitor several factors in the upcoming quarters: (1) Sustained enrollment growth at Chamberlain and Walden, particularly with new campuses opening; (2) Student outcomes and adoption rates from AI-driven learning initiatives and credential programs; (3) Advancement in employer partnerships aimed at improving student placement and institutional relevance. Successful execution of campus developments and leadership integrations will also be critical indicators. Covista shares are currently trading at $128.79, up from $117 prior to the earnings announcement. Is the company at a pivotal moment that suggests a buy or sell? Discover more in our comprehensive research report (free for active Edge members). Additionally, discover our Top 5 Growth Stocks report. High-growth stocks, like Meta, CrowdStrike, and Broadcom, which our AI recently flagged, returned 315%, 314%, and 455%, respectively. Find out which five stocks our AI is highlighting this month—free of charge. Access our Top 5 Growth Stocks HERE. Stocks featured in our report include prominent names such as Nvidia (with a remarkable 1,326% growth between June 2020 and June 2025) alongside lesser-known companies like Comfort Systems, which showed a 782% return over five years. Uncover your potential next big investment with StockStory today.
